An earlier meta-analysis of three GWAS identified 30 significant and 10 suggestive susceptibility loci for Crohn's disease 2 . The average confidence interval surrounding these loci was 233 kb (with a range of 20-1,140 kb), encompassing 4.1 genes (range 0-37 genes), for a total of 153 positional candidates (Supplementary Table 1) .
We decided to sequence the open reading frame (ORF) and intronexon boundaries of the 51 genes mapping to loci containing between one and five genes. For loci with more than six candidates, we retained 15 genes that mapped to significant networks identified when analyzing all candidates with Ingenuity Pathways (v8.5) (Supplementary Table 2 ). To these 66 genes, we added the SLC22A4 candidate (ref. 16 ), as well as PTGER4, ORMDL3 and GSDMB, on the basis of previously reported cis expression quantitative trait loci effects 2, 17 . The list of the 70 selected genes is provided in Supplementary Table 3 .
After extensive optimization (Supplementary Note), we selected a protocol involving (i) constitution of equimolar pools of genomic DNA from sets of 32 cases or controls, (ii) amplification, using Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes Oy), of the 70 targeted ORFs and intron-exon boundaries as a series of 1,045 amplicons averaging 222 bp in length (range 136-337 bp), (iii) equimolar pooling of ~300 amplicons, (iv) massive parallel pyrosequencing using the Roche FLX system 18 targeting an average sequence depth of 500 for both the Watson and Crick (W&C) strands and (v) detection of DNA sequence variants (DSVs) using the Amplicon Variant Analyzer (AVA) software (Roche) augmented with custom-made scripts (Online Methods).
We opted for a staged design in which all 70 candidate genes were first sequenced in 112 cases and 112 controls (stage I). This provided 98.5% and 73.3% nominal power (P ≤ 0.05) to detect the 12% and 7% excess of rare NOD2 (Gene ID: 64127) variants reported in references 14 and 15, respectively. The most promising genes were further
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease l e t t e r s evaluated in additional pools of cases and controls (stage II). To increase the impact of genetic effects other than NOD2, we selected 112 stage I cases that did not carry any of three known NOD2 susceptibility variants (p.Arg702Trp, p.Gly908Arg and p.Ala1007fs). To avoid subtle stratification, the corresponding 112 controls underwent the same selection. All analyzed cases and controls were of European decent.
We could sequence 92.9% of the amplicons, corresponding to 63 out of the 70 genes (Supplementary Table 3 ) and a total of 108.3 kb, with coverage of at least 200 for both W&C strands in at least one case and one control pool. Simulations indicate that this coverage provided at least 83.4% power to detect singletons (that is, one variant chromosome in a DNA pool of 32 individuals), given the settings of the AVA software and the self-imposed curation filters (Supplementary Fig. 1 ). The average sequence depth (± standard deviation (s.d.)) of the retained amplicons was 1,471 ± 849 in cases and 1,420 ± 822 in controls (Supplementary Table 3 ). Analysis of the flowgrams yielded 372 DSVs ( Table 1 and Supplementary Table 4) . Transitions accounted for 82.5% of the variants, transversions for 16.1%, dinucleotide substitutions for 0.3% and indels for 1.1%. Synonymous variants accounted for 41.7% of the variants, missense variants for 55.9%, nonsense variants for 0.8%, in-frame indels for 1.1% and 'boundary' (intronic, within 2 bp of an exon) (β) variants for 0.5%. DSVs with an estimated minor allele frequency (MAF) <0.05 amounted to 78.5%, whereas singletons represented 50.3% of all variants (Fig. 1) . As expected and reflecting purifying selection on mildly deleterious variants, the frequency spectrum of non-synonymous variants was shifted toward lower frequencies when compared to synonymous variants. Nonsynonymous variants represented 60% of the variants with MAF < 0.05 compared to 40% of variants with MAF ≥ 0.05 (Table 1 and Fig. 1) . The high transition to transversion ratio (5.1) is thought to be due to (i) the analysis of ORFs, as transversions are more likely to be nonsynonymous and are therefore selected against, (ii) idiosyncrasies of the analyzed set of genes, as their transition to transversion ratio tended to be higher than that of other ORFs in the HapMap data and (iii) the elimination of low frequency (<2.5% frequency) C>A = G>T variants (Supplementary Table 5 and Supplementary Note).
We evaluated our protocol in terms of sensitivity (that is, the fraction of true variants called), positive predictive value (PPV, the fraction of true variants among called variants) and accuracy in estimating allelic frequency, focusing first on common variants (MAF ≥ 0.05). Analysis of the HapMap data identified 62 bona fide SNPs with MAF ≥ 0.05 that were covered by the 879 retained amplicons. Five of these amplicons (8.1%) resided within 6 bp of a homopolymer track and were thus ignored (Online Methods). The remaining 57 amplicons were all detected, indicating excellent sensitivity. The 24 called SNPs with MAF ≥ 0.05 that were not genotyped in HapMap were inventoried in the dbSNP database (22 out of 24 SNPs) or confirmed by the 1000 Genomes Project data (see URLs) (the remaining two SNPs not inventoried in dbSNP), indicating excellent PPV. To evaluate the accuracy in estimating allelic frequencies, we took advantage of 31 common SNPs that had been genotyped on the same individuals as part of other projects. Supplementary Figure 2 shows the correlation between allelic frequencies estimated from the genotyping data and the read counts. The regression coefficient was 0.975 and the correlation was 0.993.
To obtain similar estimates for rare variants, we manually (Sanger sequencing on the ABI 3730) sequenced 2,283 bp of the NOD2 ORF in the same 112 cases and 112 controls. Sanger sequencing identified 38 variants with MAF < 0.05. Assuming faultless Sanger sequencing, the sensitivity and PPV of the massive parallel resequencing protocol were 82.4% and 97.9%, respectively. Frequency estimates from the read counts tended to underestimate the actual frequencies of the rare variants (regression coefficient = 0.822, correlation = 0.578) ( Supplementary  Fig. 2 ). We observed no difference in sequence depth between the amplicon by DNA pool combinations in which rare DSVs were detected and those in which no such DSVs were found (Supplementary Fig. 3) .
Having evaluated the performance of our protocol, we searched for differences in the cumulative frequencies of rare variants (MAF < 0.05) between cases and controls. We estimated the statistical significance of the observed differences on a gene-by-gene basis using a permutation test (Online Methods). We computed the P values for synonymous variants, all non-synonymous plus β variants and non-synonymous variants predicted by SIFT 19 to be damaging. For each gene by DSVtype combination, we computed two P values corresponding, respectively, to an enrichment of rare variants in cases (risk variants) or an enrichment of rare variants in controls (protective variants). Thus, we hypothesized that disruptive variants would increase disease risk in some genes and decrease disease risk in others. After applying a Bonferroni correction, none of the 63 sequenced genes showed a A>C=T>G corresponds to an A to C or T to G transversion where A and T are the ancestral alleles as determined from the analysis of orthologues primate sequences. All other substitutions follow this nomenclature scheme. IF-INDEL corresponds to in-frame insertion-deletion events. Boundary corresponds to splice site variants located within 2-bp from an exon boundary. l e t t e r s significant (P < 7.94 × 10 −4 ) enrichment of rare variants either in cases or in controls, whether synonymous, non-synonymous plus β or damaging (Supplementary Table 6 ). There was no evidence for a difference in the distribution of P values between synonymous and nonsynonymous plus β variants, whether considering variants independently or on a gene-by-gene basis (Supplementary Note). However, NOD2 showed the expected enrichment of rare non-synonymous variants (excluding the well-known p.Arg702Trp, p.Gly908Arg and p.Ala1007fs variants) in cases (nominal P = 5.94 × 10 −3 ; rank 3). We therefore decided to pursue sequencing (stage II) of the top 20% of genes (that is, 12 genes) in 288-928 additional cases and 288-1,216 additional controls, depending on intermediate results.
The procedure we used was identical to that in stage I, that is, highthroughput resequencing of pooled amplicons obtained from DNA pools of cases or controls (32 individuals per pool and up to 29 case and 38 control pools per gene). We appended amplicons with DNA pool-specific tags, which allowed simultaneous sequencing of multiple DNA pools. The average sequence depth in stage II was 988 ± 512 (range 411-13,506) in cases and 1,019 ± 415 (range 405-10,414) in controls ( Supplementary Fig. 1 and Supplementary Table 3 ). We detected two new common and 112 new rare variants (Supplementary Table 7) . We observed no difference in sequence depth between the amplicon by DNA pool combinations in which rare DSVs were detected and those in which no such DSVs were found (Supplementary Fig. 3) .
We tested for differences in the cumulative frequencies of rare variants in cases and controls using the same permutation test as above except that here we only tested the significance of enrichment with the same polarity as in stage I, meaning enrichment either for rare risk variants in cases (FGFR1OP, GSDMB, IKZF3, IL1RL1, NOD2, SLC9A4 or TNFSF8) or rare protective variants in controls (CCL8, CDKAL1, ENOX1, IL23R or SLC22A5). In the stage II analysis ( Table 2) , one gene yielded a suggestive association (FGFR1OP, Gene ID: 11116; nominal P = 0.040, Bonferroni-corrected P = 0.386), and one gene yielded a significant association (IL23R, Gene ID: 149233; nominal P = 2.67 × 10 −3 , Bonferroni-corrected P = 0.0314).
Closer examination of FGFR1OP showed that three non-synonymous variants (p.Thr184Ile, p.Lys251Asn and p.Ser281Pro), located within 2,436 bp of each other, segregated identically across DNA pools, strongly suggesting that they were in complete linkage disequilibrium. When considering these variants as a single event, nominal P values dropped to 0.124 in stage I and to 0.081 in stage II. Hence, FGFR1OP was not considered for further analysis.
The IL23R signal was entirely due to three variants (p.Arg86Gln, p.Gly149Arg and p.Val362Ile), with a cumulative frequency of 0.0052 in cases compared to 0.0370 in controls in stage I and 0.0088 in cases compared to 0.0193 in controls in stage II ( Table 3 and Supplementary Table 8 ). The observation of an enrichment in controls of their presumably protective IL23R variants was consistent with the protective effect of p.Arg381Gln that lead to the discovery of IL23R in a previous GWAS 20 . p.Arg381Gln was enriched in our controls as expected (P = 8.49 × 10 −9 ).
The fact that these IL23R variants are low frequency rather than very rare DSVs 4 allowed targeted genotyping in independent samples. We developed TaqMan assays for p.Arg86Gln, p.Gly149Arg (Table 3 and Supplementary Fig. 2 ). We then genotyped an additional 1,565 individuals with Crohn's disease, 2,000 controls and 3,101 familial samples (740 affected and 2,361 non-affected individuals) (stage III). All analyzed individuals were of European decent and most of them were previously used in GWAS replications. p.Gly149Arg (P = 0.022) and p.Val362Ile (P = 1.51 × 10 −3 ) were significantly enriched in controls in the replication cohort, and we observed a similar trend, albeit not formally significant, for the rarer p.Arg86Gln variant (P = 0.057) ( Table 4) . p.Arg381Gln confers protection against ulcerative colitis 20 as well. We thus genotyped a cohort of 1,251 ulcerative colitis cases of European decent for the same four IL23R variants. Both p.Arg381Gln (P = 9.03 × 10 −9 ) and p.Val362Ile (P = 8.31 × 10 −3 ) were significantly depleted in ulcerative colitis cases, whereas we observed the expected trend for p.Gly149Arg (P = 0.087) but not for p.Arg86Gln (P = 0.613) ( Table 5) .
We herein describe the systematic search for rare coding variants influencing inherited predisposition to Crohn's disease in 63 positional candidates identified by GWAS. We report three new low frequency IL23R variants protecting against Crohn's disease: p.Arg86Gln, p.Gly149Arg and p.Val362Ile. The three same variants were found to be protective in an independent study, strengthening our claims (M. Rivas & M. Daly, personal communication). We present preliminary evidence that p.Gly149Arg and p.Val362Ile act protectively against ulcerative colitis as well, as would be expected from the equivalent effect of p.Arg381Gln.
As was the case for the previously described p.Arg381Gln variant, the newly described p.Arg86Gln, p.Gly149Arg and p.Val362Ile variants are assumed to be hypomorphs that dampen IL23R signaling. p.Gly149Arg and p.Arg381Gln affect extremely conserved residues in the extracellular and intracellular domain of the receptor, respectively, and are predicted by SIFT 19 to be damaging. p.Arg86Gln and p.Val362Ile, on the contrary, affect poorly conserved residues and are predicted by SIFT 19 (using sequence information only) to be 'tolerated' and by PolyPhen 21 (using both sequence and structural information) to be 'benign' . Moreover, the reference IL23R sequences of some mammals carry the glutamine and isoleucine residues associated with inflammatory bowel disease in humans. Although we cannot exclude the possibility that p.Arg86Gln and p.Val362Ile are enriched in controls because of their association with causative variants lying outside the coding region, we consider it more parsimonious that they affect IL23R signaling directly. Of note, relative protection conferred by the 'damaging' p.Gly149Arg and p.Arg381Gln variants (2.98 and 2.75) tended to be higher than that conferred by the 'tolerated' p.Arg86Gln and p.Val362Ile variants (2.50 and 1.76), and we observed the same tendency for ulcerative colitis.
Relative protection against Crohn's disease conferred by the newly detected low frequency variants was ~2.4, on average. Although a possible overestimation (due to winner's curse), this value appears considerably larger than the ~1.2 relative risk conferred by most common variants detected in GWAS and supports an increase in effect size with decreasing frequency 6 . However, the newly detected variants jointly explain only ~0.44% of the variance of the underlying liability, compared with ~1.23% explained by the more common p.Arg381Gln and rs7517847 variants 19 (Supplementary Note). Haplotype analysis indicated that the protection conferred by p.Arg86Gln, p.Gly149Arg and p.Val362Ile is largely independent of the more common p.Arg381Gln and rs7517847 variants (Supplementary Table 9 ). Thus, we provide no evidence for 'synthetic association' 22 at the IL23R locus (Supplementary Note).
Although not significant when accounting for multiple testing, we obtained evidence suggesting an enrichment of rare non-synonymous NOD2 risk variants in cases in stage I, supporting the results presented in previous reports 14, 15 . We did not confirm this enrichment in stage II despite the sequencing of 928 cases and 992 controls. This discrepancy may be related to the selection of stage I samples not carrying the previously described p.Arg702Trp, p.Gly908Arg or p.Ala1007fs NOD2 susceptibility variants, which were consequently enriched in stage 12 , in which researchers resequenced the ORF and regulatory regions of ten candidate genes for type 1 diabetes in 480 cases and 480 controls and reported four low frequency protective variants in IFIH1. These modest success rates contrast with the findings of another previous study 13 , in which researchers reported an enrichment of rare variants associated with hypertriglyceridemia (defined as fasting plasma triglyceride concentrations above the ninety-fifth percentile) in all four resequenced (438 cases and 327 controls) candidate genes from GWAS (APOA5, GCKR, LPL and APOB). Simulation studies indicate that this discrepancy is more likely to result from a difference in the genomic architecture of the studied traits rather than from methodological idiosyncrasies (high-throughput sequencing of DNA pools in two stages versus Sanger sequencing of individual samples in one stage) (Supplementary Table 10 and Supplementary Note).
This study confirms the enrichment of low frequency variants (either in cases or controls) in at least some genes underlying inherited predisposition to complex diseases. Our results support an increase in effect size with decreasing variant frequency. However, because of their frequency, rare variants explain less of the heritability than their common counterparts. Achieving adequate power to reliably detect low frequency variants will require resequencing of cohorts larger than those used in this study. This will become increasingly feasible as sequencing technology continues to improve. The demonstration of an enrichment of rare or low frequency variants in candidate genes could then become an effective way to demonstrate the causality of candidate genes from GWAS.
oNLINe MeTHoDS
High-throughput pyrosequencing on Roche FLX. Genomic DNA concentrations were determined by Quant-iT PicoGreen dsDNA Reagent and Kits (Invitrogen) for the constitution of equimolar pools of 32 cases or controls (except one pool of 48 in stage I). Primer pairs for PCR were selected using Primer 3 (ref. 23) , avoiding known SNP positions. Amplicon-specific PCR reactions were set up in 30 µl volumes containg 6 µl of 5× Phusion HF buffer, 200 µM of each dNTP, 0.5 µM of each primer and 0.6 U of Phusion HighFidelity DNA Polymerase (Finnzymes Oy). Cycling conditions were 98 °C for 2 min, 32 cycles at 98 °C for 10 s, 60 °C for 30 s and 72 °C for 15 s, followed by 72 °C for 10 min on a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems). PCR products were purified using MultiScreen PCR µ96 Filter Plates (Millipore) and quantified with the Quant-iT PicoGreen dsDNA reagent and kit. Up to 300 amplicons were combined in equimolar ratios. Pooled amplicons were concentrated using the Montage PCR Filter Units (Millipore) and purified using the AMPure kit (Agencourt Biosciences). The final concentration and length distribution were measured using the Experion DNA 1K Analysis kit (Bio-Rad) on the Experion Automated Electrophoresis Station (Bio-Rad). High-throughput pyrosequencing was carried out using both primer A and B on a Roche 454 Genome Sequencer FLX instrument following the recommendations of the manufacturer 18 .
DSV detection. Image and data were processed with the Genome Sequencer FLX System Software Package (Roche). DSVs were extracted from sff files using the AVA software. AVA reports DSVs if they are observed at least four times and represent ≥ 0.5% of the reads. From the AVA-generated list, we eliminated DSVs based on the following criteria: (i) not observed on both W&C strands, (ii) having flanking DSVs within 2 bp on both sides, (iii) in or within 6 bp from a homopolymer (≥5×) track and (iv) corresponding to C>A or G>T substitutions with frequency <0.025 (Supplementary Note).
Testing for a differential load of rare variants in cases and controls from resequencing data. The excess load of rare variants in cases (risk variants) or controls (protective variants) was tested on a gene-by-gene basis, and within each gene by DSV variant type (synonymous, non-synonymous plus β, or damaging). Rare variants were defined as DSVs with MAF < 0.05. The results were essentially unaffected by the threshold frequency used to define rare variants (MAF < 0.02-0.05) (data not shown). DSV read counts (number of reads with the DSV per total number of reads for that amplicon) were converted to the closest chromosome counts (>0) (number of chromosomes with the DSV per total number of chromosomes in the pool = 64) and these were summed over DNA pools separately for cases and controls. The P value of the difference in DSV chromosome counts between cases and controls was then computed using two one-tailed Fisher's exact tests, one testing an excess in cases (risk) and the other in controls (protective). For a given gene, we then multiplied hypothesis-specific (risk and protective) P values across rare variants to generate two gene-specific summary P values. The statistical significance of these summary statistics was estimated by permutation testing. For each rare DSV, case versus control status of the mutant chromosomes were assigned randomly, but accounting for the possibility that the number of successfully sequenced chromosomes (that is, DNA pools) might differ between cases and controls. The same two gene-specific summary P values were generated for 1,000,000 permutations, and the significance of the P values obtained with the real data was estimated as the proportion of permutations with a lower, hypothesisspecific, summary P value.
Case-control and familial association test based on individual genotypes. SNPs were tested on individual DNA using custom TaqMan assays (Applied Biosystems). The statistical significance of the difference in DSV frequency between cases and controls was estimated using a one-sided Fisher's exact test. The familial cohort was used to evaluate the significance of the distorted segregation (transmission disequilibrium test (TDT)) of the DSVs p.Arg381Gln and p.Val362Ile from heterozygous parents to affected offspring using a custommade script. As no heterozygous parents were available in the familial cohort for p.Arg86Gln and p.Gly149Arg, one affected individual per family was added to the case cohort in the case-control analysis for the analysis of these variants. We combined test statistics across resequencing, case-control and TDT experiments using a permutation test akin to the one described above.
